Lv610
2504 积分 2022-08-12 加入
NSCLC: Five trials to watch
38分钟前
求助中
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
17小时前
已完结
Research Summary An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
17小时前
已完结
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
17小时前
已完结
Hijacking ERAD for targeted degradation of transmembrane proteins
19小时前
已完结
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1天前
已完结
Bispecific antibodies: a mechanistic review of the pipeline
4天前
已完结
The present and future of bispecific antibodies for cancer therapy
4天前
已完结
Targeting RNA structures with small molecules
4天前
已完结
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
4天前
已完结
皖公网安备34019202002308
